Stock Market & Financial Investment News

Edwards Lifesciences upgraded to Outperform from Market Perform at Wells FargoWells Fargo upgraded Edwards Lifesciences citing a number of positive developments since it downgraded the stock in December 2013, including strong Q4 Sapien results outside the U.S. and the company's successful first-inman transcatheter mitral valve implants. Wells raised its price target range for shares to $82-$83 from $67-$69.